Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas

Histopathology

Volumn 54, Issue 6, 2009, Pages 688-698

  Marquard, Lena ^a,b,c   Poulsen, Christian B ^b,d   Gjerdrum, Lise Mette ^b   De Nully Brown, Peter ^d   Christensen, Ib J ^e   Jensen, Peter B ^a,c   Sehested, Maxwell ^b,c   Johansen, Preben ^f   Ralfkiær, Elisabeth ^b  

^a Mental Health Services CPH   (Denmark)

^b Experimental Pathology Unit   (Denmark)

^c BioAlliance Pharma   (France)

^d Copenhagen Biocentre ^*  (Denmark)

^e FINSEN LABORATORY   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acetylation; Diffuse large B cell lymphoma; Histone deacetylases; Histone H4; Immunohistochemistry; Peripheral T cell lymphoma; Survival; Unspecified

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 6; HISTONE H4; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOID TISSUE; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; T CELL LYMPHOMA;

ACETYLATION; CELL LINE, TUMOR; HISTONE DEACETYLASES; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, T-CELL, PERIPHERAL; REPRESSOR PROTEINS;

EID: 65349137584     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03290.x     Document Type: Article

References (79)

1. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In Jaffe ES, Harris NL, Stein H, Vardiman JW eds. Pathology and genetics: tumours of haematopoietic and lymphoid tissues. Lyon : IARC Press, 2001 171 174.
2. Jaffe ES, Ralfkiaer E. Mature T-cell and NK-cell neoplasms: introduction. In Jaffe ES, Harris NL, Stein H, Vardiman JW eds. Pathology and genetics: tumours of haematopoietic and lymphoid tissues. Lyon : IARC Press, 2001 191 194.
3. Savage KJ. Peripheral T-cell lymphomas. Blood Rev. 2007 21 201 216. (Pubitemid 46880004)
4. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 103 275 282. (Pubitemid 38029949)
5. Berglund M, Thunberg U, Amini RM et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod. Pathol. 2005 18 1113 1120. (Pubitemid 41224503)
6. Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997 90 244 251. (Pubitemid 27276568)
7. Lossos IS, Jones CD, Warnke R et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001 98 945 951.
8. Poulsen CB, Borup R, Borregaard N, Nielsen FC, Moller MB, Ralfkiaer E. Prognostic significance of metallothionein in B-cell lymphomas. Blood 2006 108 3514 3519.
9. Sjo LD, Poulsen CB, Hansen M, Moller MB, Ralfkiaer E. Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur. J. Haematol. 2007 79 501 507. (Pubitemid 350126679)
10. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002 346 1937 1947. (Pubitemid 34651353)
11. Gallamini A, Stelitano C, Calvi R et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004 103 2474 2479. (Pubitemid 38392996)
12. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann. Oncol. 2004 15 1467 1475. (Pubitemid 39409735)
13. Lopez-Guillermo A, Cid J, Salar A et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification. Ann. Oncol. 1998 9 849 855. (Pubitemid 28440443)
14. Ishida T, Inagaki H, Utsunomiya A et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin. Cancer Res. 2004 10 5494 5500. (Pubitemid 39100487)
15. Ralfkiaer E, Müller-Hermelink HK, Jaffe ES. Peripheral T-cell lymphoma, unspecified. In Jaffe ES, Harris NL, Stein H, Vardiman JW eds. Pathology and genetics: tumours of haematopoietic and lymphoid tissues. Lyon : IARC Press, 2001 227 229.
16. Foss F, Pohlman B, Jacobsen E et al. Phase II open-label trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. EMSO Conference. Ann. Onc. 2008 19 154 Abstract 241.
17. Piekarz RL, Frye R, Wright J et al. Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. J. Clin. Oncol. (Meeting Abstracts) 2007 25 8027.
18. Prince HM, George D, Patnaik A et al. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-Hodgkin's lymphoma. J. Clin. Oncol. (Meeting Abstracts) 2007 25 3500.
19. Duvic M, Olsen EA, Breneman D et al. Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides prolonged safety and clinical benefit to patients with advanced cutaneous T-cell lymphoma (CTCL). ASH Annual Meeting Abstracts. Blood 2007 110 2582.
20. O'Connor OA, Heaney ML, Schwartz L et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 2006 24 166 173. (Pubitemid 46630509)
21. Crump M, Coiffier B, Jacobsen ED et al. Oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma (DLBCL): final results of a phase II trial. J. Clin. Oncol. (Meeting Abstract) 2007 25 18511.
22. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003 370 737 749. (Pubitemid 36399066)
23. Schafer S, Jung M. Chromatin modifications as targets for new anticancer drugs. Arch. Pharm. (Weinheim) 2005 338 347 357. (Pubitemid 41169994)
24. Khan N, Jeffers M, Kumar S et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008 409 581 589.
25. Bi G, Jiang G. The molecular mechanism of HDAC inhibitors in anticancer effects. Cell. Mol. Immunol. 2006 3 285 290.
26. Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem. Biophys. Res. Commun. 2001 287 705 713. (Pubitemid 32912772)
27. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004 59 177 189. (Pubitemid 38481229)
28. Choi JH, Kwon HJ, Yoon BI et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn. J. Cancer Res. 2001 92 1300 1304. (Pubitemid 34036893)
29. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004 5 455 463. (Pubitemid 38610247)
30. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr., Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998 391 811 814. (Pubitemid 28099682)
31. Kim MS, Kwon HJ, Lee YM et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 2001 7 437 443. (Pubitemid 32298546)
32. Marquard L, Petersen KD, Persson M, Hoff KD, Jensen PB, Sehested M. Monitoring the effect of belinostat in solid tumors by H4 acetylation. APMIS 2008 116 382 392.
33. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon : IARC Press, 2001.
34. Poulsen CB, Borup R, Nielsen FC et al. Microarray-based classification of diffuse large B-cell lymphoma. Eur. J. Haematol. 2005 74 453 465.
35. Ronzoni S, Faretta M, Ballarini M, Pelicci P, Minucci S. New method to detect histone acetylation levels by flow cytometry. Cytometry A 2005 66 52 61. (Pubitemid 40868919)
36. Wilson AJ, Byun DS, Popova N et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 2006 281 13548 13558. (Pubitemid 43855268)
37. Song J, Noh JH, Lee JH et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005 113 264 268. (Pubitemid 40676807)
38. Sasaki H, Moriyama S, Nakashima Y et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004 46 171 178. (Pubitemid 39330411)
39. Krusche CA, Wulfing P, Kersting C et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treat. 2005 90 15 23. (Pubitemid 40486997)
40. Ishihama K, Yamakawa M, Semba S et al. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J. Clin. Pathol. 2007 60 1205 1210. (Pubitemid 350084539)
41. Weichert W, Roske A, Gekeler V et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 2008 98 604 610.
42. Huang BH, Laban M, Leung CH et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005 12 395 404. (Pubitemid 40520691)
43. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 2003 310 529 536. (Pubitemid 37163696)
44. Senese S, Zaragoza K, Minardi S et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol. Cell. Biol. 2007 27 4784 4795. (Pubitemid 47016131)
45. Hideshima T, Bradner JE, Wong J et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl Acad. Sci. USA 2005 102 8567 8572. (Pubitemid 40862776)
46. Bali P, Pranpat M, Bradner J et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 2005 280 26729 26734. (Pubitemid 41040705)
47. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem. Pharmacol. 2007 74 659 671. (Pubitemid 47096639)
48. Yang WM, Yao YL, Sun JM, Davie JR, Seto E. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J. Biol. Chem. 1997 272 28001 28007. (Pubitemid 27473607)
49. Grozinger CM, Hassig CA, Schreiber SL. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl Acad. Sci. USA 1999 96 4868 4873. (Pubitemid 29214503)
50. Fischle W, Emiliani S, Hendzel MJ et al. A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. J. Biol. Chem. 1999 274 11713 11720. (Pubitemid 129518426)
51. Dangond F, Hafler DA, Tong JK et al. Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells. Biochem. Biophys. Res. Commun. 1998 242 648 652. (Pubitemid 28412582)
52. Emiliani S, Fischle W, Van LC, Al-Abed Y, Verdin E. Characterization of a human RPD3 ortholog, HDAC3. Proc. Natl Acad. Sci. USA 1998 95 2795 2800. (Pubitemid 28135808)
53. Hu E, Chen Z, Fredrickson T et al. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J. Biol. Chem. 2000 275 15254 15264. (Pubitemid 30337251)
54. Wang AH, Bertos NR, Vezmar M et al. HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol. Cell. Biol. 1999 19 7816 7827. (Pubitemid 29493445)
55. Kao HY, Downes M, Ordentlich P, Evans RM. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev. 2000 14 55 66. (Pubitemid 30051579)
56. Zhou X, Marks PA, Rifkind RA, Richon VM. Cloning and characterization of a histone deacetylase, HDAC9. Proc. Natl Acad. Sci. USA 2001 98 10572 10577. (Pubitemid 32878662)
57. Hrzenjak A, Moinfar F, Kremser ML et al. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Ther. 2006 5 2203 2210. (Pubitemid 44530456)
58. Pelicci P, Minucci S, Piccini D, et al. G2M Cancer Drugs AG D, assignee. Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylase. Patent WO2004/029622.
59. Zhang Z, Yamashita H, Toyama T et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res. Treat. 2005 94 11 16. (Pubitemid 41416937)
60. Rikimaru T, Taketomi A, Yamashita Y et al. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 2007 72 69 74. (Pubitemid 350249132)
61. Weichert W, Roske A, Gekeler V et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008 9 139 148. (Pubitemid 350160080)
62. Weichert W, Roske A, Niesporek S et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res. 2008 14 1669 1677.
63. Cabrero JR, Serrador JM, Barreiro O et al. Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol. Biol. Cell 2006 17 3435 3445. (Pubitemid 44156438)
64. Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008 53 267 277.
65. Zhang Z, Yamashita H, Toyama T et al. HDAC6 expression is correlated with better survival in breast cancer. Clin. Cancer Res. 2004 10 6962 6968. (Pubitemid 39383047)
66. Saji S, Kawakami M, Hayashi S et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005 24 4531 4539. (Pubitemid 41032616)
67. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int. J. Cancer 2004 112 26 32. (Pubitemid 39249488)
68. Seligson DB, Horvath S, Shi T et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005 435 1262 1266. (Pubitemid 40943093)
69. Toh Y, Ohga T, Endo K et al. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int. J. Cancer 2004 110 362 367. (Pubitemid 38649886)
70. Mitchell TJ, John S. Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology 2005 114 301 312. (Pubitemid 40314803)
71. Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Wasik MA. STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc. Natl Acad. Sci. USA 2005 102 6948 6953. (Pubitemid 40675422)
72. Sommer VH, Clemmensen OJ, Nielsen O et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 2004 18 1288 1295. (Pubitemid 39023140)
73. Rimsza LM, Roberts RA, Miller TP et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and lymphoma molecular profiling project. Blood 2004 103 4251 4258. (Pubitemid 38685371)
74. Magner WJ, Tomasi TB. Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes. Mol. Immunol. 2005 42 1033 1042. (Pubitemid 40501838)
75. Gialitakis M, Kretsovali A, Spilianakis C et al. Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A. Nucleic Acids Res. 2006 34 765 772. (Pubitemid 43380662)
76. Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol. Cell. Biol. 2005 25 1608 1619. (Pubitemid 40280131)
77. Dhordain P, Lin RJ, Quief S et al. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res. 1998 26 4645 4651. (Pubitemid 28466611)
78. Wong CW, Privalsky ML. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6. J. Biol. Chem. 1998 273 27695 27702. (Pubitemid 28500495)
79. Pasqualucci L, Bereschenko O, Niu H et al. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk. Lymphoma 2003 44 (Suppl. 3 5 12. (Pubitemid 38196057)